172 related articles for article (PubMed ID: 35600862)
1. TCR Coexpression Signature Predicts Immunotherapy Resistance in NSCLC.
Wang Y; Liu Y; Li X; Li W; Xue Z; He X; Xiong W; He L; Bai Y
Front Pharmacol; 2022; 13():875149. PubMed ID: 35600862
[No Abstract] [Full Text] [Related]
2. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
Li X; Wang Y; Li X; Feng G; Hu S; Bai Y
Front Immunol; 2021; 12():638763. PubMed ID: 34305884
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
Front Immunol; 2021; 12():665002. PubMed ID: 34367132
[TBL] [Abstract][Full Text] [Related]
4. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
Yan Y; Wang X; Liu C; Jia J
BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
[TBL] [Abstract][Full Text] [Related]
5. Identification of immune-related gene signature for non-small cell lung cancer patients with immune checkpoint inhibitors.
Wang L; Han C; Cai C; Wu J; Chen J; Su C
Heliyon; 2024 Mar; 10(5):e26974. PubMed ID: 38463866
[TBL] [Abstract][Full Text] [Related]
6. Prognosis of Non-small-cell Lung Cancer Patients With Lipid Metabolism Pathway Alternations to Immunotherapy.
Cheng T; Zhang J; Liu D; Lai G; Wen X
Front Genet; 2021; 12():646362. PubMed ID: 34335679
[TBL] [Abstract][Full Text] [Related]
7.
Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
[TBL] [Abstract][Full Text] [Related]
8. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.
Zhang X; Shi X; Zhao H; Jia X; Yang Y
Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis.
Lin X; Deng J; Deng H; Yang Y; Sun N; Zhou M; Qin Y; Xie X; Li S; Zhong N; Song Y; Zhou C
Front Immunol; 2021; 12():818492. PubMed ID: 35095920
[TBL] [Abstract][Full Text] [Related]
10. Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma.
Li L; Lu G; Liu Y; Gong L; Zheng X; Zheng H; Gu W; Yang L
Front Oncol; 2021; 11():658690. PubMed ID: 34150625
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Smoking on the Immune Microenvironment and Immunogenicity and Its Relationship With the Prognosis of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
Sun Y; Yang Q; Shen J; Wei T; Shen W; Zhang N; Luo P; Zhang J
Front Cell Dev Biol; 2021; 9():745859. PubMed ID: 34660603
[No Abstract] [Full Text] [Related]
12. Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients.
Wang Z; Wang C; Lin S; Yu X
Front Oncol; 2021; 11():725292. PubMed ID: 34513703
[TBL] [Abstract][Full Text] [Related]
13. PTPRO-related CD8
Dong H; Xie C; Yao Z; Zhao R; Lin Y; Luo Y; Chen S; Qin Y; Chen Y; Zhang H
Front Immunol; 2022; 13():947841. PubMed ID: 36003382
[TBL] [Abstract][Full Text] [Related]
14. A Novel Pyroptotic and Inflammatory Gene Signature Predicts the Prognosis of Cutaneous Melanoma and the Effect of Anticancer Therapies.
Xu Y; Chen Y; Niu Z; Xing J; Yang Z; Yin X; Guo L; Zhang Q; Qiu H; Han Y
Front Med (Lausanne); 2022; 9():841568. PubMed ID: 35492358
[TBL] [Abstract][Full Text] [Related]
15. A signature of tumor immune microenvironment genes associated with the prognosis of non‑small cell lung cancer.
Li J; Li X; Zhang C; Zhang C; Wang H
Oncol Rep; 2020 Mar; 43(3):795-806. PubMed ID: 32020214
[TBL] [Abstract][Full Text] [Related]
16. Fatty Acid Metabolic Signaling Pathway Alternation Predict Prognosis of Immune Checkpoint Inhibitors in Glioblastoma.
Liu R; Liang W; Hua Q; Wu L; Wang X; Li Q; Zhong F; Li B; Qiu Z
Front Immunol; 2022; 13():819515. PubMed ID: 35251000
[TBL] [Abstract][Full Text] [Related]
17.
Wang T; Luo Y; Zhang Q; Shen Y; Peng M; Huang P; Zhou Z; Wu X; Chen K
J Thorac Dis; 2022 Mar; 14(3):729-740. PubMed ID: 35399232
[TBL] [Abstract][Full Text] [Related]
18. Effect of mesenchymal-epithelial transition amplification on immune microenvironment and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer.
Su S; Lin A; Luo P; Zou J; Huang Z; Wang X; Zeng Y; Cen W; Zhang X; Huang H; Hu J; Zhang J
Ann Transl Med; 2021 Sep; 9(18):1475. PubMed ID: 34734027
[TBL] [Abstract][Full Text] [Related]
19. TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Lin A; Zhang H; Meng H; Deng Z; Gu T; Luo P; Zhang J
Front Immunol; 2021; 12():667875. PubMed ID: 34603277
[TBL] [Abstract][Full Text] [Related]
20. MYCBP2 expression correlated with inflammatory cell infiltration and prognosis immunotherapy in thyroid cancer patients.
Wang G; Miao C; Mo L; Kahlert UD; Wu J; Ou M; Huang R; Feng R; Pang W; Shi W
Front Immunol; 2022; 13():1048503. PubMed ID: 36582246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
